 Lavanya Kondapalli
Concepts (125)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 12 | 2024 | 2666 | 1.990 |
Why?
| | Cardiovascular Diseases | 7 | 2025 | 2113 | 1.080 |
Why?
| | Myocardial Infarction | 3 | 2023 | 1045 | 1.020 |
Why?
| | Menopause, Premature | 1 | 2025 | 12 | 0.960 |
Why?
| | Antineoplastic Agents | 4 | 2024 | 2145 | 0.860 |
Why?
| | Carcinoid Heart Disease | 1 | 2022 | 2 | 0.810 |
Why?
| | Cancer Survivors | 4 | 2024 | 280 | 0.700 |
Why?
| | Pyridazines | 1 | 2020 | 56 | 0.650 |
Why?
| | Myocarditis | 1 | 2021 | 101 | 0.650 |
Why?
| | Carotid Stenosis | 1 | 2020 | 91 | 0.620 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2020 | 121 | 0.620 |
Why?
| | Imidazoles | 1 | 2020 | 244 | 0.610 |
Why?
| | Protein Kinase Inhibitors | 2 | 2020 | 920 | 0.580 |
Why?
| | Cardiotoxicity | 3 | 2024 | 34 | 0.550 |
Why?
| | Immunotherapy | 2 | 2023 | 647 | 0.530 |
Why?
| | Atherosclerosis | 1 | 2020 | 415 | 0.510 |
Why?
| | Thrombosis | 1 | 2020 | 368 | 0.510 |
Why?
| | Triple Negative Breast Neoplasms | 3 | 2023 | 202 | 0.490 |
Why?
| | Anticoagulants | 1 | 2020 | 665 | 0.470 |
Why?
| | Anthracyclines | 5 | 2024 | 49 | 0.410 |
Why?
| | Stroke | 2 | 2025 | 1129 | 0.390 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 1079 | 0.380 |
Why?
| | Chorionic Gonadotropin | 1 | 2012 | 80 | 0.380 |
Why?
| | Fertilization in Vitro | 1 | 2012 | 83 | 0.370 |
Why?
| | Breast Neoplasms | 4 | 2023 | 2249 | 0.310 |
Why?
| | Medical Oncology | 2 | 2022 | 290 | 0.310 |
Why?
| | Estradiol | 1 | 2012 | 513 | 0.300 |
Why?
| | Lung Neoplasms | 1 | 2021 | 2494 | 0.280 |
Why?
| | Humans | 25 | 2025 | 137514 | 0.270 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2025 | 38 | 0.240 |
Why?
| | England | 1 | 2023 | 99 | 0.200 |
Why?
| | Risk Factors | 6 | 2025 | 10356 | 0.200 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2025 | 176 | 0.200 |
Why?
| | Morbidity | 1 | 2022 | 322 | 0.180 |
Why?
| | Biology | 1 | 2021 | 87 | 0.170 |
Why?
| | Immune System | 1 | 2021 | 177 | 0.170 |
Why?
| | Survivors | 1 | 2024 | 489 | 0.170 |
Why?
| | Molecular Targeted Therapy | 2 | 2020 | 414 | 0.170 |
Why?
| | Heart Failure | 2 | 2023 | 2222 | 0.160 |
Why?
| | Antihypertensive Agents | 1 | 2024 | 493 | 0.160 |
Why?
| | Fusion Proteins, bcr-abl | 1 | 2020 | 69 | 0.160 |
Why?
| | Heart Diseases | 1 | 2023 | 359 | 0.160 |
Why?
| | Catheter Ablation | 2 | 2014 | 349 | 0.160 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2021 | 252 | 0.150 |
Why?
| | Atrial Fibrillation | 2 | 2014 | 390 | 0.150 |
Why?
| | Drug Interactions | 1 | 2020 | 409 | 0.150 |
Why?
| | Immunologic Factors | 1 | 2020 | 239 | 0.150 |
Why?
| | Taxoids | 3 | 2023 | 104 | 0.150 |
Why?
| | Hypertension | 2 | 2025 | 1293 | 0.140 |
Why?
| | Cardiology | 1 | 2020 | 279 | 0.140 |
Why?
| | Skin Neoplasms | 1 | 2005 | 853 | 0.140 |
Why?
| | United States | 7 | 2025 | 14696 | 0.140 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2023 | 392 | 0.140 |
Why?
| | Societies, Medical | 1 | 2020 | 820 | 0.130 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 1 | 2015 | 21 | 0.120 |
Why?
| | Female | 10 | 2025 | 73162 | 0.110 |
Why?
| | Treatment Outcome | 4 | 2020 | 10821 | 0.110 |
Why?
| | Biomarkers, Tumor | 1 | 2021 | 1279 | 0.110 |
Why?
| | Anesthesia, General | 1 | 2014 | 73 | 0.110 |
Why?
| | Pandemics | 1 | 2022 | 1619 | 0.110 |
Why?
| | Aged | 7 | 2023 | 23798 | 0.100 |
Why?
| | Medicare | 3 | 2023 | 747 | 0.100 |
Why?
| | Micromanipulation | 1 | 2012 | 14 | 0.100 |
Why?
| | Birth Rate | 1 | 2012 | 30 | 0.100 |
Why?
| | Embryo Transfer | 1 | 2012 | 32 | 0.100 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 363 | 0.100 |
Why?
| | Oocytes | 1 | 2012 | 176 | 0.090 |
Why?
| | Nanoparticles | 1 | 2015 | 484 | 0.080 |
Why?
| | Pregnancy Outcome | 1 | 2012 | 413 | 0.080 |
Why?
| | Odds Ratio | 1 | 2012 | 1063 | 0.080 |
Why?
| | Inflammation | 1 | 2020 | 2837 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 1695 | 0.080 |
Why?
| | Disease Management | 2 | 2024 | 625 | 0.070 |
Why?
| | Child | 1 | 2024 | 22037 | 0.050 |
Why?
| | Forecasting | 1 | 2005 | 386 | 0.050 |
Why?
| | Electrophysiologic Techniques, Cardiac | 2 | 2014 | 82 | 0.050 |
Why?
| | Protein Kinases | 1 | 2005 | 319 | 0.050 |
Why?
| | Cohort Studies | 1 | 2012 | 5730 | 0.050 |
Why?
| | Arrhythmias, Cardiac | 1 | 2023 | 331 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2005 | 1047 | 0.040 |
Why?
| | American Heart Association | 1 | 2021 | 306 | 0.040 |
Why?
| | Immunotherapy, Adoptive | 1 | 2023 | 324 | 0.040 |
Why?
| | Cardiotonic Agents | 1 | 2020 | 126 | 0.040 |
Why?
| | Pregnancy | 1 | 2012 | 6745 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2021 | 892 | 0.040 |
Why?
| | Coronary Artery Disease | 1 | 2025 | 703 | 0.040 |
Why?
| | Melanoma | 1 | 2005 | 758 | 0.040 |
Why?
| | Prevalence | 1 | 2025 | 2719 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 344 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2021 | 1377 | 0.030 |
Why?
| | Blood Pressure | 1 | 2024 | 1776 | 0.030 |
Why?
| | Middle Aged | 3 | 2014 | 33355 | 0.030 |
Why?
| | Dibenzocycloheptenes | 1 | 2015 | 2 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1618 | 0.030 |
Why?
| | Biological Availability | 1 | 2015 | 151 | 0.030 |
Why?
| | Administration, Cutaneous | 1 | 2015 | 128 | 0.030 |
Why?
| | Drug Compounding | 1 | 2015 | 98 | 0.030 |
Why?
| | Solubility | 1 | 2015 | 249 | 0.030 |
Why?
| | Philadelphia | 1 | 2014 | 49 | 0.030 |
Why?
| | Rats, Wistar | 1 | 2015 | 457 | 0.030 |
Why?
| | Retrospective Studies | 1 | 2012 | 15628 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2015 | 566 | 0.030 |
Why?
| | Adrenergic beta-Agonists | 1 | 2014 | 133 | 0.030 |
Why?
| | Conscious Sedation | 1 | 2014 | 93 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2015 | 595 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1580 | 0.020 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2012 | 115 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2012 | 533 | 0.020 |
Why?
| | Decision Making | 1 | 2018 | 906 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3439 | 0.020 |
Why?
| | Age Factors | 1 | 2018 | 3301 | 0.020 |
Why?
| | Smoking | 1 | 2018 | 1639 | 0.020 |
Why?
| | Reoperation | 1 | 2012 | 569 | 0.020 |
Why?
| | Adult | 1 | 2012 | 37821 | 0.020 |
Why?
| | Recurrence | 1 | 2012 | 1060 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2014 | 2039 | 0.020 |
Why?
| | Incidence | 1 | 2014 | 2792 | 0.020 |
Why?
| | Logistic Models | 1 | 2012 | 2064 | 0.020 |
Why?
| | Rats | 1 | 2015 | 5676 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2014 | 3546 | 0.020 |
Why?
| | Animals | 2 | 2020 | 37011 | 0.020 |
Why?
| | Obesity | 1 | 2018 | 2974 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2012 | 5139 | 0.010 |
Why?
| | Male | 3 | 2015 | 67718 | 0.010 |
Why?
| | Prospective Studies | 1 | 2014 | 7598 | 0.010 |
Why?
|
|
Kondapalli's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|